Aherne Sinéad T, Madden Stephen F, Hughes David J, Pardini Barbara, Naccarati Alessio, Levy Miroslav, Vodicka Pavel, Neary Paul, Dowling Paul, Clynes Martin
Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Department of Physiology and Medical Physics and Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
BMC Cancer. 2015 Apr 30;15:329. doi: 10.1186/s12885-015-1327-5.
Screening for the early detection of colorectal cancer is important to improve patient survival. The aim of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency at delineating patients with polyps and benign adenomas from normal and cancer patient groups.
The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal, polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset of 40 CRC samples and paired normal tissues.
High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent public dataset of forty CRC samples and paired normal tissues was confirmed.
We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.
筛查结直肠癌以实现早期检测对于提高患者生存率至关重要。本研究的目的是探讨循环游离微小RNA作为结直肠癌生物标志物的潜力，以及它们在区分息肉和良性腺瘤患者与正常及癌症患者组方面的效能。
在一个由48份血浆样本组成的发现集中评估了667种微小RNA的表达，这些样本包括正常、息肉、腺瘤以及早期和晚期癌症样本。在一个由97名受试者组成的验证队列中进一步检测了三种微小RNA（miR-34a、miR-150和miR-923），该队列分为相同的五组，同时还在一个包含40份结直肠癌样本及配对正常组织的独立公共数据集中进行了检测。
循环miR-34a水平高和miR-150水平低可将息肉患者组与晚期癌症患者组区分开来（曲线下面积=0.904）；循环miR-150水平低可将腺瘤患者与晚期癌症患者区分开来（曲线下面积=0.875）。此外，在一个包含40份结直肠癌样本及配对正常组织的独立公共数据集中，miR-34a和miR-150的表达改变得到了证实。
我们鉴定出两种循环微小RNA，它们能够区分患有不同结肠疾病的患者组，以及区分晚期癌症患者与良性疾病患者组。
